Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Obstacles exist in facilitating hepatitis C virus (HCV) care cascade. To increase timely and accurate diagnosis, disease awareness and accessibility, in-hospital HCV reflex testing followed by automatic appointments and a late call-back strategy (R.N.A. model) was applied. We aimed to compare the HCV treatment rate of patients treated with this strategy compared to those without. Methods: One hundred and twenty-five anti-HCV seropositive patients who adopted the R.N.A. model in 2020 and another 1,396 controls treated in 2019 were enrolled to compare the gaps in accurate HCV RNA diagnosis to final treatment allocation. Results: The HCV RNA testing rate was significantly higher in patients who received reflex testing than in those without reflex testing (100% vs. 84.8%, P<0.001). When patients were stratified according to the referring outpatient department, a significant improvement in the HCV RNA testing rate was particularly noted in patients from non-hepatology departments (100% vs. 23.3%, P<0.001). The treatment rate in HCV RNA seropositive patients was 83% (83/100) after the adoption of the R.N.A. model, among whom 96.1% and 73.9% of patients were from the hepatology and non-hepatology departments, respectively. Compared to subjects without R.N.A. model application, a significant improvement in the treatment rate was observed for patients from non-hepatology departments (73.9% vs. 27.8%, P=0.001). The application of the R.N.A. model significantly increased the in-hospital HCV treatment uptake from 6.4% to 73.9% for patients from non-hepatology departments (P<0.001). Conclusions: The care cascade increased the treatment uptake and set up a model for enhancing in-hospital HCV elimination.
Abstract
Background/Aims: Obstacles exist in facilitating hepatitis C virus (HCV) care cascade. To increase timely and accurate diagnosis, disease awareness and accessibility, in-hospital HCV reflex testing followed by automatic appointments and a late call-back strategy (R.N.A. model) was applied. We aimed to compare the HCV treatment rate of patients treated with this strategy compared to those without. Methods: One hundred and twenty-five anti-HCV seropositive patients who adopted the R.N.A. model in 2020 and another 1,396 controls treated in 2019 were enrolled to compare the gaps in accurate HCV RNA diagnosis to final treatment allocation. Results: The HCV RNA testing rate was significantly higher in patients who received reflex testing than in those without reflex testing (100% vs. 84.8%, P<0.001). When patients were stratified according to the referring outpatient department, a significant improvement in the HCV RNA testing rate was particularly noted in patients from non-hepatology departments (100% vs. 23.3%, P<0.001). The treatment rate in HCV RNA seropositive patients was 83% (83/100) after the adoption of the R.N.A. model, among whom 96.1% and 73.9% of patients were from the hepatology and non-hepatology departments, respectively. Compared to subjects without R.N.A. model application, a significant improvement in the treatment rate was observed for patients from non-hepatology departments (73.9% vs. 27.8%, P=0.001). The application of the R.N.A. model significantly increased the in-hospital HCV treatment uptake from 6.4% to 73.9% for patients from non-hepatology departments (P<0.001). Conclusions: The care cascade increased the treatment uptake and set up a model for enhancing in-hospital HCV elimination.
참고문헌 (26)
- "Hepatitis C"[URL]
- Yu ML, "Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan", Medicine (Baltimore), 94, pp.e690~ (2015)
- Yang JF, "Viral hepatitis infections in southern Taiwan: a multicenter community-based study", Kaohsiung J Med Sci, 26, pp.461~469 (2010)
- Chen YY, "Secular trends and geographic maps of hepatitis C virus infection among 4million blood donors in Taiwan from 1999 to 2017", Hepatol Commun, 4, pp.1193~1205 (2020)
- "Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis"[URL]
- Huang CF, "Directacting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C consortium", Hepatol Int, 13, pp.587~598 (2019)
- Huang CF, "Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study", BMJ Open, 9, pp.e026703~ (2019)
- Chung-Feng Huang, "Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy", Clinical and Molecular Hepatology, 26(3), pp.251~260 (2020), 대한간학회[DOI]
- Turner BJ, "Hepatitis C virus screening and care: complexity of implementation in primary care practices serving disadvantaged populations", Ann Intern Med, 171, pp.865~874 (2019)
- McGibbon E, "Half a diagnosis: gap in confirming infection among hepatitis C antibody-positive patients", Am J Med, 126, pp.718~722 (2013)
- Chevaliez S, "Strategies for the improvement of HCV testing and diagnosis", Expert Rev Anti Infect Ther, 17, pp.341~347 (2019)
- Crespo J, "Hepatitis C reflex testing in Spain in 2019: a story of success", Enferm Infecc Microbiol Clin (2020)[DOI]
- Yu ML, "2020 Taiwan consensus statement on the management of hepatitis C:part (I) general population", J Formos Med Assoc, 119, pp.1019~1040 (2020)
- Yu ML, "2020 Taiwan consensus statement on the management of hepatitis C:part (II) special populations", J Formos Med Assoc, 119, pp.1135~1157 (2020)
- "Ministry of Health and Welfare"[URL]
- Vermehren J, "Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C", J Clin Virol, 52, pp.133~137 (2011)
- Hirsch AA, "Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis", Jt Comm J Qual Patient Saf, 40, pp.351~357 (2014)
- Gale HB, "Comparison of serial hepatitis C virus detection in samples submitted through serology for reflex confirmation versus samples directly submitted for quantitation", J Clin Microbiol, 49, pp.3036~3039 (2011)
- Hsieh MH, "Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection", PLoS One, 9, pp.e94791~ (2014)
- Tai CM, "Integrated care for methadone maintenance patients with hepatitis C virus infection", Kaohsiung J Med Sci, 35, pp.501~507 (2019)
- Yu ML, "High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients", J Hepatol, 60, pp.253~259 (2014)
- Huang CF, "Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics", Hepatol Int, 8, pp.224~232 (2014)
- Huang CF, "Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients", Kidney Int, 97, pp.421~ (2020)
- "COVID-19 (SARS-CoV-2 Infection) case number update"[URL]
- Fix OK, "Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement", Hepatology, 72, pp.287~304 (2020)
- Wong GL, "Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement", Lancet Gastroenterol Hepatol, 5, pp.776~787 (2020)